IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly
Authors' conclusion
Our results demonstrated that initial IGF-I levels during SD-Lanreotide predicted the biochemical outcome after 12 months of HF-Lanreotide. Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen.
Study context
- Population
- Patients with acromegaly treated with Lanreotide
- Participants
- 67 vs 102
- Exposure
- HF-Lanreotide after SD-Lanreotide failure
- HF-Lanreotiden = 67
- SD-Lanreotiden = 102
- Outcome
- Predictors of response to long-term high frequency (HF)-fg-SRLs
- Follow-up
- 12 months of HF-Lanreotide
Main finding
As reported in the abstract
Predictors of response at 12 months of HF-Lanreotide
- IGF-I reached at 6 months of SD-Lanreotide predicted response
- p = 0.04
- IGF-I reached at 6 months of HF-Lanreotide predicted response
- p = 0.01
Observational data: associations, not effects.
Further findings
- Controlled · 6 months of SD-Lanreotide — SD-Lanreotide
- 27.4%
- Controlled · 12 months of SD-Lanreotide — SD-Lanreotide
- 34.3%
- Controlled at 6 months and remained controlled until 12 months · 6 to 12 months of HF-Lanreotide — HF-Lanreotide
- 26.9%
IGF-I change over treatment (SD and HF-Lanreotide) · first 6 months; 6 to 12 months
- IGF-I reduced during first six months
- P < 0.001
- No further significant reduction between 6 and 12 months
Predictor of response at 12 months of SD-Lanreotide
- IGF-I reached at 6 months of SD-Lanreotide predicted response
- P = 0.024
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly. Pituitary. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →